The preliminary data for all the Phase 2a subjects in hRPC clinical trial for retinal disease is expected to be reported in the second half of 2019. Phase 2b clinical trial of CTX cell therapy candidate for stroke disability has already commenced.
ReNeuron is developing ExoPr0, the first CTX-derived exosome candidate, to deliver third-party biological drugs. To explore the use of exosome, ReNeuron has signed a collaboration agreement with a US-based biopharmaceutical company creating delivery vehicles for synthetic oligonucleotides used in gene therapy.
ReNeuron’s revenue from their license agreement with Fosun Pharma, coupled with existing financial resources of the company, will be sufficient to support the company’s operations for at least the next 12 months.
Olav Hellebø, CEO of ReNeuron, said: “Both the hRPC and CTX studies are expected to continue to yield meaningful clinical data during the course of 2019 and 2020.”